Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure

Bibliography

• Puig JG, Calvo C, Luurila O, Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens 2007;12:917-24
   Google Scholar
• Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs 2007;67:95-106.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006;24:185-92
   PubMed Web of Science ®Google Scholar
• Theobald K, Capan M, Herbold M, Quality assurance in non-interventional studies. Ger Med Sci 2009;7:doc29
   PubMedGoogle Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
   PubMed Web of Science ®Google Scholar
• Steg PG, Lopez-Sendon J, Lopez de Sa E, External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007;167:68-73
   PubMedGoogle Scholar
• Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung 2010;60:124-30
   PubMed Web of Science ®Google Scholar
• Dolan E, Stanton A, Thijs L, Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005;46:156-61
   PubMed Web of Science ®Google Scholar
• Clement DL, De Buyzere ML, De Bacquer DA, Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003;348:2407-15
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008;168:2340-6
   PubMed Web of Science ®Google Scholar
• Parati G, Omboni S, Rizzoni D, The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998;16:1685-91
   PubMed Web of Science ®Google Scholar
• Mena L, Pintos S, Queipo NV, A reliable index for the prognostic significance of blood pressure variability. J Hypertens 2005;23:505-11
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Figueroa A, Baynard T, Fernhall B, Endurance training improves post-exercise cardiac autonomic modulation in obese women with and without type 2 diabetes. Eur J Appl Physiol 2007;100:437-44
   PubMed Web of Science ®Google Scholar
• Eguchi K, Ishikawa J, Hoshide S, Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens 2009;22:46-51
   PubMed Web of Science ®Google Scholar
• Rizzoni D, Muiesan ML, Salvetti M, The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 2001;19:703-11
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Schrader J, Zidek W, Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007;96:247-57
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M, Pozza G, Mosca A, Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004;17:259-66
   PubMedGoogle Scholar
• Barnett AH, Bain SC, Bouter P, Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
   PubMed Web of Science ®Google Scholar
• Luders S, Franz IW, Hilgers KF, Twenty-four hour ambulatory blood pressure monitoring [in German]. Dtsch Med Wochenschr 2005;130:2664-8
   PubMedGoogle Scholar
• Beitelshees AL, Gong Y, Bailey KR, Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. J Clin Hypertens (Greenwich) 2010;12:14-21
   PubMedGoogle Scholar
• Mengden T, Binswanger B, Weisser B, Vetter W. An evaluation of self-measured blood pressure in a study with a calcium-channel antagonist versus a beta-blocker. Am J Hypertens 1992;5:154-60
   PubMed Web of Science ®Google Scholar
• Head GA, Mihailidou AS, Duggan KA, Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ 2010;340:c1104
   PubMed Web of Science ®Google Scholar
• Leonetti G, Magnani B, Pessina AC, Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15:932-40
   PubMed Web of Science ®Google Scholar
• Lund-Johansen P, Stranden E, Helberg S, Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003;21:1003-10
   PubMed Web of Science ®Google Scholar
• Scholze J, Bida M, Hansen A, Initiation of hypertension treatment with a fixed-dose combination or its monocomponents – does it really matter? Int J Clin Pract 2006;60:265-74
   PubMed Web of Science ®Google Scholar